Theorem Clinical Research has announced the addition of RadMD, a cutting-edge medical imaging expertise company, to its roster of strategic alliances.
Theorem Clinical Research
has announced the addition of
RadMD
, a cutting-edge medical imaging expertise company, to its roster of
strategic alliances
.
“These kinds of alliances allow us to extend our capabilities to offer a greater depth and spectrum of services to our clients,” said D. Lee Spurgin Jr., Ph.D., Theorem senior vice president and general manager of medical device and diagnostic development. “When we work with partners that we already know and trust, we feel our clients get a better end result.”
With the increasing utilization of imaging in clinical research, there has been a greater demand for expertise on the use of medical imaging in clinical trials. RadMD offers unique services centered solely on the use of imaging in trials. They provide a consultative approach to implementing medical imaging endpoints based on extensive experience in the pharmaceutical development of both diagnostic and therapeutic drugs.
RadMD’s services include expertise in constructing customized medical imaging solutions, a unique worldwide network of more than 600 physicians and medical imaging experts available for independent image evaluations or “blinded reads”, regulatory strategy, imaging endpoint justification and extensive imaging training capabilities.
“We are excited to be able to bring our imaging expertise in clinical development to Theorem’s clientele, and look forward to working together to develop innovative products for our mutual customers and patients,” said Doug Stefanelli RadMD COO and executive vice president.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.